OAM
ABMD

Oppenheimer Asset Management’s Abiomed Inc ABMD Stock Holding History

Oppenheimer Asset Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-90
Closed -$15K – 1675
2019
Q4 		$15K Sell
90
-205
-69% -$38K ﹤0.01% 1471
2019
Q3 		$52K Buy
295
+2
+0.7% +$432 ﹤0.01% 1335
2019
Q2 		$76K Buy
293
+16
+6% +$4.25K ﹤0.01% 1284
2019
Q1 		$80K Sell
277
-40
-13% -$13.3K ﹤0.01% 1271
2018
Q4 		$103K Buy
+317
New +$110K ﹤0.01% 1181
2017
Q4 		– Sell
-336
Closed -$57K – 1546
2017
Q3 		$57K Buy
336
+226
+205% +$34.2K ﹤0.01% 1340
2017
Q2 		$15K Sell
110
-30
-21% -$4.03K ﹤0.01% 1492
2017
Q1 		$17K Buy
+140
New +$16.2K ﹤0.01% 1492

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Oppenheimer Asset Management's ABMD Position: Q1 2020 in Review

Oppenheimer Asset Management sold out of Abiomed Inc (ABMD) in Q1 2020, closing a stake of 90 shares — an estimated $15K sold.

Oppenheimer Asset Management first reported a position in ABMD in Q1 2017 and held it in 8 quarters. The position peaked at $103K in Q4 2018. 412 funds tracked by Wall St. Rank hold ABMD as of Q1 2020.

  • Oppenheimer Asset Management reported no remaining Abiomed Inc position as of Q1 2020 after selling out during the quarter.
  • Oppenheimer Asset Management sold 90 Abiomed Inc shares in Q1 2020, an estimated $15K.
  • Oppenheimer Asset Management first reported a position in Abiomed Inc in Q1 2017 and held it in 8 quarters.
  • Oppenheimer Asset Management's Abiomed Inc position peaked at $103K in Q4 2018.
  • 412 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2020.

Based on Oppenheimer Asset Management's 13F filing for Q1 2020, filed 8 May 2020.